View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 26, 2022

Ashvattha’s OP-101 boosts clinical outcomes in Phase IIa Covid-19 trial

According to the trial findings, OP-101 demonstrated to boost survival, in line with a rise in dosage.

Ashvattha Therapeutics has reported data from the Phase IIa PRANA clinical trial where OP-101 boosted clinical outcomes in severe Covid-19 patients.

The multicentre, placebo-controlled, double-blind, single-sequential, ascending dose trial analysed the safety, tolerability and initial efficacy of intravenous OP-101 versus placebo in severe Covid-19 patients.

In the trial, 2mg/kg, 4mg/kg and 8mg/kg doses of OP-101 were analysed in three cohorts versus a single intravenous dose of placebo.

According to the trial findings, OP-101 demonstrated to boost survival, in line with a rise in dosage.

A 2mg/kg dose of the HDT showed 67% improved survival while 4mg/kg and 8mg/kg demonstrated a 100% and 80% improvement, respectively, compared to 43% on administering placebo.

At 30 and 60 days, the risk for the composite outcome of mechanical ventilation or mortality was 18% in the combined OP-101 treatment groups versus 71% in the placebo arm.

Three out of seven placebo-treated subjects and 14 of 17 who received OP-101 were alive at 60 days while those subjects in the OP-101 arms did not need mechanical ventilation.

OP-101 was linked to attenuating neuronal injury markers NfL and GFAP, which lasted until day 30 of the trial.

Furthermore, 4mg/kg of OP-101 substantially lowered hyperinflammation markers TNF-α, IL-6 and IL-8.

No cases of drug-associated adverse events were observed in the trial.

A hydroxyl dendrimer therapeutic (HDT) with N-acetyl cysteine (NAC), OP-101 is administered intravenously.

It acts on reactive macrophages and microglia, which cause hyperinflammation, injury to the lungs and multi-organ failure due to viral or bacterial infections, including Covid-19.

Ashvattha Therapeutics chairman and CEO Jeffrey Clelland said: “We are incredibly pleased with these positive results that support the potential of OP-101 to significantly improve clinical outcomes and survival for patients with severe Covid-19.

“This data also validates the ability of our hydroxyl dendrimer therapies to cross tissue barriers, including blood-brain barriers, selectively targeting areas of inflammation with an excellent safety profile, which could benefit patients with other diseases characterised by inflammation.”

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena